Diakonos Research Ltd
Diakonos Research Ltd is a clinical-stage biotechnology company based in Houston, TX, specializing in the development of a groundbreaking Dendritic Cell Vaccine (DCV) for difficult-to-treat cancers. Their proprietary double-loading technique tricks the body into perceiving cancer cells as virally infected cells, harnessing the body's natural anti-viral immune response to fight cancer.
Powered by a groundbreaking discovery on the immune system, Diakonos' DCV, known as DOC1021, is based on how dendritic cells detect and respond to viral threats. By mobilizing formidable CD8 CD161 T cells, the immune system is activated to destroy what it believes are infected cells throughout the body. With FDA Fast Track designation and Orphan Drug designation for malignant glioma, Diakonos is at the forefront of redefining the potential of immunotherapy in the fight against cancer.
Generated from the website
Also at this address
You might also like
Partial Data by Infogroup (c) 2024. All rights reserved.